Biotech Values

[p3analyze]

JB, Scher asked a trick question and implied the frozen provenge killed patients. Data said otherwise, as David pointed out, those who received frozen provenge lived longer than those who didn't. I guess that is not sufficient to answer the trick question, and you jumped on it.

While the decision to receive frozen provenge may be confounded with survival, there is no evidence that it did any harm, certainly not by the overall nomogram predicted survival for the placebo arm, or the fact that placebo arm performed as well as the taxotere arm in Tx327 study.

If you were Maha Hussain, you would have accused me of cross-trial comparison. Which is fine, now consider this. You said "men did not cross over could be because they were at a worse point in their disease progression and did not have the physical or mental capacity to try yet another experimental procedure". Continuing on that line of logic, those who chose taxotere over frozen provenge would have to be better off than those who did not, because we all know taxotere is more toxic and patients would have to be really tough physically before an oncologist wants to risk the side effects. Then explain to me how come those chemo only placebo had a worse survival than those who crossed over to frozen provenge if it were harmful and it got in the way of the life saving taxotere?

From
http://investor.dendreon.com/ReleaseDetail.cfm?ReleaseID=218144&Header=News
See
The median survival was 25.7 months for patients who received APC8015F followed by docetaxel. In contrast, the median survival was 20.2 months for patients who received placebo only and subsequent treatment with docetaxel, a 14.3 month difference compared to 34.5 month median survival seen in the patients who received initial treatment with PROVENGE followed by docetaxel

lest me forget- shame on you jellybean.